Eysz

Eysz addresses a critical diagnostic challenge in pediatric primary care: distinguishing between Childhood Absence Epilepsy (CAE) and Attention-Deficit/Hyperactivity Disorder (ADHD), which present with similar symptoms like staring and inattention. The company's core product is the Eysz HyperventilationRecorder, an FDA-registered Class II medical device that uses a gamified mobile application to guide a hyperventilation procedure—a known trigger for absence seizures—and records objective video data for clinical review. Validated in an NIH-funded study, the device offers a scalable, in-office tool to improve diagnostic accuracy, reduce unnecessary neurology referrals, and optimize treatment pathways for common pediatric neurobehavioral conditions.

FDA-registered HyperventilationRecorder combining a gamified mobile application for patient engagement with objective video recording and clinical reporting software for in-office screening of absence seizures.

Direct competition is limited; the gold-standard vEEG is resource-intensive and not used for screening. Eysz's main competitors are subjective clinical history and screening questionnaires, which lack objectivity. The company's primary challenge is displacing these entrenched, albeit inadequate, methods rather than competing with similar devices.